top of page

Search

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

blonca9
1 day ago
1 min read

CEO Nicki Thompson describes why she believes the company is differentied in the field, and how TRIMTECH's construct is designed to selectively degrade aggregates that cause neurodegeneration.

Recent Posts

On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress

On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress

After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection

After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page